Position in EXEL
as of Jun 30, 2026
· filed Jul 14, 2026
Position Value
$3,437,242
+$935,812 QoQ
Shares Held
63,173
+8.3% QoQ
Ownership
0.025%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#44
of 316 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CWA Asset Management Group, LLC holds $28,091,999 across 13 Biotechnology names. EXEL ranks #3 (12.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
83,249 | $9,437,106 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
19,619 | $4,727,590 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
63,173 | $3,437,242 | |
| 4 | AUPH |
Aurinia Pharmaceuticals Inc.
|
202,440 | $3,435,406 | |
| 5 | TBPH |
Theravance Biopharma, Inc.
|
134,994 | $2,294,898 | |
| 6 | HRMY |
Harmony Biosciences Holdings, Inc.
|
61,273 | $2,230,949 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,623 | $1,012,005 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
10,500 | $821,835 |
All Filings in EXEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,437,242 | 63,173 | Shares | Sole | 2026-07-14 | |
| 2026-03-31 | $2,501,430 | 58,322 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $2,105,374 | 48,035 | Shares | Sole | 2026-01-07 | |
| 2025-09-30 | $1,947,584 | 47,157 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $1,860,660 | 42,211 | Shares | Sole | 2025-07-17 | |
| 2025-03-31 | $1,339,494 | 36,281 | Shares | Sole | 2025-04-21 | |
| 2024-12-31 | $905,793 | 27,201 | Shares | Sole | 2025-01-06 | |
| 2024-09-30 | $576,660 | 22,222 | Shares | Sole | 2024-11-01 | |
| 2024-03-31 | $238,106 | 10,034 | Shares | Sole | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||